...
首页> 外文期刊>European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology >Safety and efficacy of MitraClip MitraClip ? therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions ( TRAMI TRAMI ) registry
【24h】

Safety and efficacy of MitraClip MitraClip ? therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions ( TRAMI TRAMI ) registry

机译:Mitroaclip Mitraaclip的安全性和有效性? 左心室喷射分数严重受损的患者治疗:德国经截面二尖瓣干预(轨道电路)注册表的结果

获取原文
获取原文并翻译 | 示例
           

摘要

Aims The aim of the present study was to assess the safety and efficacy of percutaneous mitral valve repair using the MitraClip ? device in patients with severely reduced systolic left ventricular ( LV ) function. Methods and results Among 777 MitraClip ? implantations included in the German mitral valve registry, we identified 256 patients suffering from severely reduced LV function [ejection fraction ( EF ) 30%] in whom successful percutaneous mitral valve repair was performed. Procedural safety, efficacy, and 1‐year outcome was compared with 241 patients with preserved LV function ( EF 50%) and 280 patients presenting with an EF 30–50% prior to MitraClip ? therapy. High procedural success rates, low periprocedural complication rates, and low residual mitral regurgitation grades at discharge were achieved throughout all groups. In‐hospital mortality was low and comparable in all groups. After 1 year, mortality rates were 24.2% ( EF 30%), 17.3% ( EF 30–50%), and 18.9% ( EF 50%). Major adverse cardiac or cardiovascular event rates were 29.7% ( EF 30%), 24.4% ( EF 30–50%), and 23.5% ( EF 50%). Procedural failure was the main predictor for mortality in EF 30% patients (hazard ratio 10.38; 95% CI 3.71–29.02). Improved clinical symptoms were observed in the majority of patients in all groups. Thus, 69.5% of EF 30% patients improved by one or more New York Heart Association functional class. Compared with patients with preserved LV function, this is a significantly larger proportion (EF 50%: 56.8%; P 0.05). Moreover, quality of life, being very poor at baseline, improved distinctively in severe heart failure patients. Conclusion In patients with severely reduced systolic LV function undergoing MitraClip ? therapy, procedural safety, efficacy, and clinical improvement after 1 year are comparable to patients with preserved LV function.
机译:目的是本研究的目的是评估使用Mitraclip的经皮二尖瓣修复的安全性和功效?患者的装置严重减少收缩期左心室(LV)功能。 777 Mitroaclip之间的方法和结果?植入中包括在德国二尖瓣登记处,我们确定了256名患有严重减少的LV功能的患者[射血分数(EF)& 30%]进行了成功的经皮二尖瓣修复。将程序安全性,疗效和1年结果与241名患者的保存的LV函数(EF&GT; 50%)进行比较,280名患者在MITRACLIP之前用EF 30-50%呈现效果?治疗。在所有组内实现了高程序成功率,低脉冲复杂性并发症率和低残留二尖瓣再诊所等级。在医院死亡率低且各组织相当。 1年后,死亡率为24.2%(EF& 30%),17.3%(EF 30-50%)和18.9%(EF&GT; 50%)。主要的不良心脏或心血管事件率为29.7%(EF <30%),24.4%(EF 30-50%)和23.5%(EF&GT; 50%)。程序失败是EF& 30%患者死亡率的主要预测因子(危险比10.38; 95%CI 3.71-29.02)。在所有群体中大多数患者中观察到改善临床症状。因此,69.5%的EF& 30%的患者通过一个或多个纽约心脏协会功能阶层改善。与保存的LV功能患者相比,这是一个显着更大的比例(EF& 50%:56.8%; P <0.05)。而且,生活质量,基线非常差,在严重的心力衰竭患者中鲜明地改善。结论患者严重降低的收缩液LV函数接受MITRACLIP? 1年后的治疗,程序安全性,疗效和临床改善与保存的LV功能患者相媲美。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号